Infigratinib
Truseltiq (infigratinib) is an oral targeted therapy known as a fibroblast growth factor receptor (FGFR) inhibitor, specifically designed for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 fusion or rearrangement. This medication represents a precision medicine approach for patients whose tumors have a specific genetic alteration.
Truseltiq is an FGFR inhibitor used to treat FGFR2-altered cholangiocarcinoma in adults after prior systemic therapy.
Key facts at a glance
- RxNorm
- 2551006
- Generic
- Truseltiq
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Truseltiq is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or other rearrangements. Patient selection should be based on confirmation of FGFR2 alteration through FDA-approved testing.
Truseltiq is a kinase inhibitor that targets and blocks the activity of fibroblast growth factor receptors (FGFR), particularly FGFR2. By inhibiting FGFR signaling in tumor cells that harbor FGFR2 fusions or rearrangements, it helps to slow or stop cancer cell growth and proliferation.
Common side effects may include nail toxicity, stomatitis, dry skin, and visual disturbances. Truseltiq may cause fetal harm and should not be used during pregnancy. Patients should have baseline eye exams and monitoring for liver function and phosphate levels. Drug interactions may occur with certain CYP3A4 inducers and inhibitors.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy